Study assessing the impact of depression and anxiety on prostate cancer patients' quality of life

Prospective assessment of psychological and vasomotor side effects of testosterone deprivation and assessment of ageing males’ symptoms scale in prostate cancer patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN79584810

Enrollment

150

Registered

2021-07-27

Start date

2005-03-01

Completion date

Unknown

Last updated

2021-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer Malignant neoplasm of prostate

Interventions

Patients were administered quality of life (QOL) questionnaires and rating scale questionnaires at specific time points before, during and after completion of hormone therapy. Hormone therapy duration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients with prostate cancer starting LHRH agonist therapy, irrespective of stage 2. Ability to give informed consent 3. Performance status 0-2 4. Life expectancy should be more than 6 months

Exclusion criteria

Exclusion criteria: 1. Past or present history of psychiatric problem 2. If a patient scores greater than 11 on the baseline Hospital and Anxiety Scale they will be offered anti-depressant drug treatment and/or a psychiatric referral. In addition they will be asked if they wished to continue in the study. If the patients do not wish to continue at this stage the researchers would not collect any further quality of life information from them 3. Concurrent steroid therapy or treatment with any other antipsychotic/antidepressant/sedative drugs 4. Brain metastases 5. Concurrent radiotherapy 6. Major surgery in last 6 months, e.g. prostatectomy, colectomy etc 7. Major medical illness in last 6 months e.g. pulmonary embolism, myocardial infarction, cerebrovascular accident etc

Design outcomes

Primary

Measure	Time frame
Measured before, during and after completion of hormone therapy: 1. Anxiety and depression measured using the Hospital Anxiety and Depression Scale 2. Severity of symptoms related to aging measured using the Aging Males’ Symptoms (AMS) scale 3. Quality of life measured using the EORTC QLQ-C30 questionnaire 4. Symptoms measured using the non-specific symptom (NSS) checklist 5. Health anxiety measured using the Whiteley Index 6. Erectile dysunction measured using an abridged version of the IIEF SCALE	—

Measure

Time frame

Measured before, during and after completion of hormone therapy: 1. Anxiety and depression measured using the Hospital Anxiety and Depression Scale 2. Severity of symptoms related to aging measured using the Aging Males’ Symptoms (AMS) scale 3. Quality of life measured using the EORTC QLQ-C30 questionnaire 4. Symptoms measured using the non-specific symptom (NSS) checklist 5. Health anxiety measured using the Whiteley Index 6. Erectile dysunction measured using an abridged version of the IIEF SCALE

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026